Editing Allergic conjunctivitis (section)

===Dual Activity Agents===
Dual-action medications are both mast cell stabilizers and antihistamines. They are the most common prescribed class of topical anti allergy agent. [[Olopatadine]] (Patanol, Pazeo)<ref>{{cite journal |vauthors=Rosenwasser LJ, O'Brien T, Weyne J |title=Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research |journal=Curr Med Res Opin |volume=21 |issue=9 |pages=1377–87 |date=September 2005 |pmid=16197656 |doi=10.1185/030079905X56547 |s2cid=8954933 }}</ref> and [[ketotifen fumarate]] (Alaway or Zaditor)<ref>{{cite journal |vauthors=Avunduk AM, Tekelioglu Y, Turk A, Akyol N |title=Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial |journal=Clin Ther |volume=27 |issue=9 |pages=1392–402 |date=September 2005 |pmid=16291412 |doi=10.1016/j.clinthera.2005.09.013 }}</ref> are both commonly prescribed. Ketotifen is available without a prescription in some countries.{{citation needed|date=October 2022|reason=where?}} However, studies demonstrates that olopatadine is more effective than ketotifen in reducing the itching associated with allergic conjunctivitis in the antigen challenge model.<ref>{{cite journal |last1=Berdy |first1=Gregg J. |last2=Spangler |first2=Dennis L. |last3=Bensch |first3=George |last4=Berdy |first4=Susan S. |last5=Brusatti |first5=Robert C. |title=Comparison of the analgesic efficacy of concurrent ibuprofen and paracetamol with ibuprofen or paracetamol alone in the management of moderate to severe acute postoperative dental pain in adolescents and adults: A randomized, double-blind, placebo-controlled, parallel-group, single-dose, two-center, modified factorial study |journal=Clinical Therapeutics |date=May 17, 2000 |volume=22 |issue=7 |pages=826–833 |doi=10.1016/S0149-2918(00)80055-7 |url=https://www.clinicaltherapeutics.com/article/S0149-2918(00)80055-7/ |pmid=10945509|url-access=subscription }}</ref>